All issues

Trials

Registrations, authorisations, readouts and what the registers actually say.

10 issues

• 2026-09-22No. 15

  The CVR is an option, and Lilly holds it

  • DEALS
  • REGULATORY
  • TRIALS
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • ABBVIE
  • OTSUKA
• 2026-09-15No. 14

  Five countries, one regulator.

  • TRIALS
  • DEALS
  • REGULATORY
  • DEFINIUM
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • GH
• 2026-09-08No. 13

  Three authorised, one counted.

  • TRIALS
  • REGULATORY
  • SLAGELSE
  • CHIETI
  • AMSTERDAM-UMC
  • ARQ
  • DEFINIUM
• 2026-09-01No. 12

  Lilly’s depression trial went from one approval to four in seven days.

  • TRIALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • ATAI-THERAPEUTICS
• 2026-08-25No. 11

  Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.

  • TRIALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • BECKLEY-PSYTECH
  • REGION-SKANE
• 2026-07-14No. 6

  Compass just put a date on the first Western psychedelic launch: the first half of 2027.

  • TRIALS
  • ACCESS
  • COMPASS
  • CYBIN
• 2026-07-07No. 5

  European psychedelic depression development just split into two camps.

  • TRIALS
  • COMPASS
  • BECKLEY-PSYTECH
  • CYBIN
• 2026-06-30No. 4

  LSD just posted the biggest depression number in psychedelic Phase 3 history.

  • TRIALS
  • RESEARCH
  • DEFINIUM
  • COMPASS
• 2026-06-23No. 3

  Europe's most advanced psychedelic Phase 3 is staked on the one indication that got harder last week.

  • TRIALS
  • RESEARCH
  • COMPASS
  • CYBIN
• 2026-06-16No. 2

  Blind the psilocybin trials in TRD, and the effect shrinks

  • RESEARCH
  • TRIALS
  • ATAIBECKLEY